Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Benjamin Djulbegovic, Rahul Mhaskar
Publikováno v:
JAMA. 320:1483
Clinical Question Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures, nonvertebral fractures, and skeletal-related events compared with placebo or no treatment? Bottom Line Am
Autor:
David Hui, Donna S. Zhukovsky, Paul Walker, Kenneth R. Hess, William Breitbart, Maxine de la Cruz, Thuc Nguyen, Diane Liu, Akhila Reddy, Daniel E. Epner, Eduardo Bruera, Janet L. Williams, Sapna Amin, Kimerson Tanco, Marieberta Vidal, Susan Frisbee-Hume, Annie Wilson, Stacy Hall, Seyedeh Dibaj, Marvin Omar Delgado-Guay
Publikováno v:
JAMA. 318:1047
The use of benzodiazepines to control agitation in delirium in the last days of life is controversial.To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of adv
Autor:
Hélène Labussière-Wallet, Natacha Maillard, Valérie Coiteux, Sylvain Chantepie, Sylvie Chevret, Ana Berceanu, Anne Huynh, Karine Risso, Didier Blaise, Anne Thiebaut-Bertrand, Reza Tabrizi, Luc-Matthieu Fornecker, Patrice Chevallier, Jason W. Chien, Regis Peffault de la Tour, Gérard Socié, Laure Vincent, Anne Bergeron, Nathalie Contentin, Angela Granata, Jacques-Olivier Bay, Sylvain Thepot, Marc Bernard
Publikováno v:
JAMA. 318:557
Importance Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post–l
Autor:
Jean-Robert Harle, Xavier Dufour, Anne-Emmanuelle Fargeton, César Cartier, Patrick Dessi, Sophie Dupuis-Girod, Alexis Ambrun, Evelyne Decullier, Sophie Rivière, Sandra Blivet, Frédéric Faure, Adeline Roux, Justin Michel, Thierry Chinet, Bettina Colombet, Brigitte Gilbert-Dussardier, Valentine Bréant, P. Lacombe, Jean-Hugues Blondel
Publikováno v:
JAMA. 316:934
Background Epistaxis is the most frequent and disabling manifestation of hereditary hemorrhagic telangiectasia (HHT). The efficacy of intravenous bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody) for epistaxis has been show